A Phase 1 Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut.
Status:
Recruiting
Trial end date:
2021-12-15
Target enrollment:
Participant gender:
Summary
This is a phase 1, single-center, randomized, double-blind, placebo-controlled study in adult
participants with peanut allergy. Participants will be randomized in a 3:1 ratio to receive
either an escalating dose of INT301 or placebo. The treatment group will be blinded to the
investigator, participants, and the Intrommune study team.